Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.409
C. Vila Gallego, M. Alvarez Lavin, M. Alonso Díez, M. Vara Urruchua, A. Revuelta Amallo, M. Inclan Conde, N. Pardo Santos, A. Aguirrezábal Arredondo, J. Muñoz Sanchez
Background and importanceIn 2019, the National Health System (NHS) approved funding for the indication of pre-exposure prophylaxis (PreP) as an strategy to prevent human immunodeficiency virus (HIV) infection in high-risk populations. The hospital pharmacy (HP), together with the Sexually Transmitted Infection (STI) centre, has created an interdisciplinary circuit where these individuals are closely monitored.Aim and objectivesTo characterise the user population of the HIV PrEP programme and assess the adequacy of the circuit, as well as the impact of the SARS-CoV-2 pandemic.Material and methodsRetrospective observational study of the PrEP programme from November 2019 to April 2021 carried out in the provincial STI treatment centre and the HP.The following were assessed: compliance with inclusion criteria, adherence to treatment and causes of discontinuation, toxicity, acquisition of STIs and interactions. Also variations during confinement and degree of involvement by COVID.Results169 males, aged 39.6±10.0 (range 19–64) years, all met at least one inclusion criterion in the last year: 75.7% (n=128) men who have sex with men (MSM) with more than 10 different sexual partners, 71.6% (n=121) MSM anal sex without condoms, 17.1% (n=29) MSM drug use, 10.7% (n=18) MSM with multiple PreP, 74.0% (n=125) MSM with at least one STI and one engaged in prostitution.30 clients discontinued medication: 33.3% (n=10) stopped risky practices, 20.0% (n=6) digestive toxicity (main adverse effect), 3.3% (n=1) poor adherence, 16.7% (n=5) client choice and 26.7% (n=8) drop out of follow-up. Mean adherence was 94.5±11.4.No patients acquired HIV during treatment, but other STIs were found (several users reported reduced of condom use): 36.7% (n=11) Treponema pallidum, 56.7% (n=17) Chlamydia trachomatis, 63.3% (n=19) Neisseria gonorrhoeae and 36.7% (n=11) Mycoplasma genitalum.This was a young population that does a lot of physical exercise and after the clinical interview it was discovered they were abusing protein shakes and anabolic steroids, therefore they were warned about it.During the confinement, 41 users were in treatment. Of the 37 who continued, 4 suffered from COVID.Conclusion and relevanceThe programme meets the requirements of the NHS, with high adherence to treatment and a good safety profile.Patients continued with PreP during confinement and there was a significant number affected by COVID.Clinical pharmaceutical follow-up has allowed preventive and corrective interventions, but more emphasis should be placed on the use of condoms and avoiding anabolic steroids given the possible renal repercussions.References and/or acknowledgementsConflict of interestNo conflict of interest
{"title":"4CPS-242 Human immunodeficiency virus pre-exposure prophylaxis: analysis, follow-up and pandemic effect","authors":"C. Vila Gallego, M. Alvarez Lavin, M. Alonso Díez, M. Vara Urruchua, A. Revuelta Amallo, M. Inclan Conde, N. Pardo Santos, A. Aguirrezábal Arredondo, J. Muñoz Sanchez","doi":"10.1136/ejhpharm-2022-eahp.409","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.409","url":null,"abstract":"Background and importanceIn 2019, the National Health System (NHS) approved funding for the indication of pre-exposure prophylaxis (PreP) as an strategy to prevent human immunodeficiency virus (HIV) infection in high-risk populations. The hospital pharmacy (HP), together with the Sexually Transmitted Infection (STI) centre, has created an interdisciplinary circuit where these individuals are closely monitored.Aim and objectivesTo characterise the user population of the HIV PrEP programme and assess the adequacy of the circuit, as well as the impact of the SARS-CoV-2 pandemic.Material and methodsRetrospective observational study of the PrEP programme from November 2019 to April 2021 carried out in the provincial STI treatment centre and the HP.The following were assessed: compliance with inclusion criteria, adherence to treatment and causes of discontinuation, toxicity, acquisition of STIs and interactions. Also variations during confinement and degree of involvement by COVID.Results169 males, aged 39.6±10.0 (range 19–64) years, all met at least one inclusion criterion in the last year: 75.7% (n=128) men who have sex with men (MSM) with more than 10 different sexual partners, 71.6% (n=121) MSM anal sex without condoms, 17.1% (n=29) MSM drug use, 10.7% (n=18) MSM with multiple PreP, 74.0% (n=125) MSM with at least one STI and one engaged in prostitution.30 clients discontinued medication: 33.3% (n=10) stopped risky practices, 20.0% (n=6) digestive toxicity (main adverse effect), 3.3% (n=1) poor adherence, 16.7% (n=5) client choice and 26.7% (n=8) drop out of follow-up. Mean adherence was 94.5±11.4.No patients acquired HIV during treatment, but other STIs were found (several users reported reduced of condom use): 36.7% (n=11) Treponema pallidum, 56.7% (n=17) Chlamydia trachomatis, 63.3% (n=19) Neisseria gonorrhoeae and 36.7% (n=11) Mycoplasma genitalum.This was a young population that does a lot of physical exercise and after the clinical interview it was discovered they were abusing protein shakes and anabolic steroids, therefore they were warned about it.During the confinement, 41 users were in treatment. Of the 37 who continued, 4 suffered from COVID.Conclusion and relevanceThe programme meets the requirements of the NHS, with high adherence to treatment and a good safety profile.Patients continued with PreP during confinement and there was a significant number affected by COVID.Clinical pharmaceutical follow-up has allowed preventive and corrective interventions, but more emphasis should be placed on the use of condoms and avoiding anabolic steroids given the possible renal repercussions.References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127106699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.424
M. Gutiérrez Lorenzo, P. Ciudad Gutiérrez, M. F. Fernández Gonzalez, P. del Valle Moreno
{"title":"5PSQ-111 Pharmaceutical intervention: avoiding interactions between antiretrovirals and vitamin supplements/antacids","authors":"M. Gutiérrez Lorenzo, P. Ciudad Gutiérrez, M. F. Fernández Gonzalez, P. del Valle Moreno","doi":"10.1136/ejhpharm-2022-eahp.424","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.424","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"135 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122978757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.406
MM Parera Pascual, G. González Morcillo, M. Bello Crespo, M. Nigorra Caro, L. Pérez de Amezaga Tomás, A. Brady Garcia, MA Crespí Cifre, M. Vilanova Boltó
{"title":"4CPS-217 Clinical, economic and organisational impact of pharmacists’ interventions in oncological care patients","authors":"MM Parera Pascual, G. González Morcillo, M. Bello Crespo, M. Nigorra Caro, L. Pérez de Amezaga Tomás, A. Brady Garcia, MA Crespí Cifre, M. Vilanova Boltó","doi":"10.1136/ejhpharm-2022-eahp.406","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.406","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121850305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.414
JI Bretones Pedrinaci, A. Martos Rosa, M. Herrera Expósito, J. Urda Romacho, M. C. Castro Vida
{"title":"4CPS-264 Analysis of medical treatment, risk factors and recurrence ofClostridioides difficilenosocomial diarrhoea","authors":"JI Bretones Pedrinaci, A. Martos Rosa, M. Herrera Expósito, J. Urda Romacho, M. C. Castro Vida","doi":"10.1136/ejhpharm-2022-eahp.414","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.414","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"103 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121986849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.417
M. Valera Rubio, MI Sierra-Torres, R. Castillejo-García, J. Cordero-Ramos, JF Álvarez-Zarallo, M. Calleja‐Hernández
Background and importanceSince December 2019, the world has faced a new disease known as COVID-19. On 11 March 2020, the World Health Organization officially declared the COVID-19 pandemic. Given the health emergency, vaccine development progressed rapidly, but with limited safety data under real-world conditions.Aim and objectivesTo describe and compare the incidence of adverse events with the BNT162b2 and mRNA-1273 COVID-19 vaccines, taking into account the number of doses and subjects previously positive for SARS-CoV-2 infection.Material and methodsA retrospective observational study was conducted in a tertiary hospital between March and April 2021. Data were collected through a questionnaire sent by email to hospital staff. Demographics and data regarding the occurrence of adverse events were collected, indicating which vaccine was administered. Statistical analysis was performed using SPSS software. Groups were compared using the Chi-square test and Fisher’s exact test when necessary.Results1249 respondents completed the survey (25% of all hospital staff);52% (650) received BNT162b2 vaccine and 48% (599) mRNA-1273. 14 402 adverse reactions were recorded. 6896 were local: 3939 were with mRNA-1273 and 2957 with BNT162b2 (6.6 vs 4.4 reactions per patient);and 7506 were systemic: 4460 with mRNA-1273 and 3046 with BNT162b2 (7.4 vs 4.7 per patient). The occurrence of local reactions was 95.8% after the first dose/89.1% after the second dose with mRNA-1273 versus 89.7%/82.5% with BNT162b2. For systemic reactions, this proportion was 64.3%/93.3% versu 46.8%/73.2% (p value<0.05).In terms of severity, 379 patients (63.3%) with mRNA-1273 confirmed a severe reaction versus 222 (34.2%) with BNT162b2 and 60 patients (10%) with mRNA-1273 confirmed an urgent reaction versus 33 (5.1%) with BNT162b2 (p value<0.001). For both vaccines, there was no difference in the occurrence of local or systemic reactions between patients seropositive and seronegative for SARS-CoV-2.Conclusion and relevanceThe results are consistent with the limited data available to date, confirming that although these are not particularly serious adverse effects, they do occur in a large majority of vaccinated persons and in greater numbers after administration of the mRNA-1273 vaccine. The Hospital Pharmacy Service is a key agent in pharmacovigilance within the healthcare system and must be aware of the safety profile of new drugs. This study is an essential tool to detect and prevent adverse events.References and/or acknowledgementsConflict of interestNo conflict of interest
自2019年12月以来，世界面临着一种名为COVID-19的新疾病。2020年3月11日，世界卫生组织正式宣布COVID-19大流行。鉴于卫生紧急情况，疫苗开发进展迅速，但在现实条件下的安全性数据有限。目的和目的描述和比较BNT162b2和mRNA-1273 COVID-19疫苗的不良事件发生率，同时考虑到先前SARS-CoV-2感染阳性的剂量和受试者数量。材料与方法回顾性观察研究于2021年3月至4月在某三级医院进行。通过电子邮件向医院工作人员发送问卷收集数据。收集了有关不良事件发生的人口统计数据和数据，表明接种了哪种疫苗。采用SPSS软件进行统计分析。组间比较采用卡方检验，必要时采用Fisher精确检验。结果1249名应答者(25%)完成了调查，52%(650人)接种了BNT162b2疫苗，48%(599人)接种了mRNA-1273疫苗。记录不良反应14402例。6896例为局部反应，3939例为mRNA-1273反应，2957例为BNT162b2反应(6.6 vs 4.4 /例);7506例为全身反应，4460例为mRNA-1273反应，3046例为BNT162b2反应(7.4 vs 4.7 /例)。mRNA-1273第一次给药后局部反应发生率为95.8% /89.1%，而BNT162b2给药后局部反应发生率为89.7%/82.5%。对于全身反应，这一比例分别为64.3%/93.3%和46.8%/73.2% (p值<0.05)。在严重程度方面，mRNA-1273组379例(63.3%)确诊为严重反应，而BNT162b2组222例(34.2%);mRNA-1273组60例(10%)确诊为紧急反应，而BNT162b2组33例(5.1%)(p值<0.001)。对于这两种疫苗，SARS-CoV-2血清阳性和血清阴性患者的局部或全身反应发生率无差异。结论和相关性研究结果与迄今为止有限的可用数据一致，证实尽管这些不是特别严重的不良反应，但它们确实发生在绝大多数接种了mRNA-1273疫苗的人身上，并且在接种了mRNA-1273疫苗后发生率更高。医院药房服务是医疗保健系统中药物警戒的关键代理人，必须了解新药的安全性。这项研究是发现和预防不良事件的重要工具。参考文献和/或致谢利益冲突无利益冲突
{"title":"5PSQ-002 Adverse events reported after administration of BNT162B2 and mRNA-1273 COVID-19 vaccines among healthcare workers","authors":"M. Valera Rubio, MI Sierra-Torres, R. Castillejo-García, J. Cordero-Ramos, JF Álvarez-Zarallo, M. Calleja‐Hernández","doi":"10.1136/ejhpharm-2022-eahp.417","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.417","url":null,"abstract":"Background and importanceSince December 2019, the world has faced a new disease known as COVID-19. On 11 March 2020, the World Health Organization officially declared the COVID-19 pandemic. Given the health emergency, vaccine development progressed rapidly, but with limited safety data under real-world conditions.Aim and objectivesTo describe and compare the incidence of adverse events with the BNT162b2 and mRNA-1273 COVID-19 vaccines, taking into account the number of doses and subjects previously positive for SARS-CoV-2 infection.Material and methodsA retrospective observational study was conducted in a tertiary hospital between March and April 2021. Data were collected through a questionnaire sent by email to hospital staff. Demographics and data regarding the occurrence of adverse events were collected, indicating which vaccine was administered. Statistical analysis was performed using SPSS software. Groups were compared using the Chi-square test and Fisher’s exact test when necessary.Results1249 respondents completed the survey (25% of all hospital staff);52% (650) received BNT162b2 vaccine and 48% (599) mRNA-1273. 14 402 adverse reactions were recorded. 6896 were local: 3939 were with mRNA-1273 and 2957 with BNT162b2 (6.6 vs 4.4 reactions per patient);and 7506 were systemic: 4460 with mRNA-1273 and 3046 with BNT162b2 (7.4 vs 4.7 per patient). The occurrence of local reactions was 95.8% after the first dose/89.1% after the second dose with mRNA-1273 versus 89.7%/82.5% with BNT162b2. For systemic reactions, this proportion was 64.3%/93.3% versu 46.8%/73.2% (p value<0.05).In terms of severity, 379 patients (63.3%) with mRNA-1273 confirmed a severe reaction versus 222 (34.2%) with BNT162b2 and 60 patients (10%) with mRNA-1273 confirmed an urgent reaction versus 33 (5.1%) with BNT162b2 (p value<0.001). For both vaccines, there was no difference in the occurrence of local or systemic reactions between patients seropositive and seronegative for SARS-CoV-2.Conclusion and relevanceThe results are consistent with the limited data available to date, confirming that although these are not particularly serious adverse effects, they do occur in a large majority of vaccinated persons and in greater numbers after administration of the mRNA-1273 vaccine. The Hospital Pharmacy Service is a key agent in pharmacovigilance within the healthcare system and must be aware of the safety profile of new drugs. This study is an essential tool to detect and prevent adverse events.References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114616841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.387
M. Larrosa García, I. Agraz Pamplona, RP Bury Macias, M. Sanz Martínez, J. Perurena Prieto, M. Martínez Gallo, M. HERNANDEZ GONZALEZ, D. Anguita Domingo, J. Montoro Ronsano, M. G. Gorgas Torner
{"title":"4CPS-062 Rituximab pharmacokinetics characterisation in plasma and urine in a patient with nephotic syndrome","authors":"M. Larrosa García, I. Agraz Pamplona, RP Bury Macias, M. Sanz Martínez, J. Perurena Prieto, M. Martínez Gallo, M. HERNANDEZ GONZALEZ, D. Anguita Domingo, J. Montoro Ronsano, M. G. Gorgas Torner","doi":"10.1136/ejhpharm-2022-eahp.387","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.387","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121449015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.418
G. Pellegrino, E. Grande, E. Bersia, E. Bastonero, M. Rebora, C. Fruttero
Background and importanceVaccines are emerging as a fundamental tool in the prevention of COVID-19 disease but are not decisive in treating it, once contracted. Anti COVID-19 monoclonal antibodies (MAb) define a valuable and parallel resource for the treatment of coronavirus infection so it is useful to monitor the usage data, adverse reactions (ADRs) and percentage of hospitalisations after treatment.Aim and objectivesPurpose of the work was to provide data on safety and efficacy of anti-COVID MAb in consideration of their use in current clinical practice.Material and methodsUsing a home-made database, the pharmacy extrapolated and reprocessed the data relating to the reports of patient recruitment by local and hospital clinicians, the number of patients who were treated, the specific therapies administered (bamlanivimab, bamlanivimab/etesevimab or casirivimab/imdevimab) and ADRs reported by doctors.In parallel, the infectious diseases department monitored the percentage of patients who still needed hospitalisation after the infusion of MAb.ResultsMost of the recruitment reports were received from general doctors (82% vs 18% from hospitals) and, from March 2021 to September 2021, 104 patients were treated: 48 patients (46.2%) with bamlanivimab/etesevimab, 55 (52.9%) with casirivimab/imdevimab and 1 (0.9%) with bamlanivimab. 67% of patients were not vaccinated while 33% received at least one dose of vaccine (58%: first dose;42%: two doses). The main comorbidity found was the cardiological/cerebral/vascular type.Following outpatient dosing, 2 ADRs have been reported: an emetic episode after bamlanivimab infusion and a subacute antero-septal myocardial infarction with acute pulmonary oedema occurring within hours after administration of casirivimab/imdevimab and in the presence of a septic event of bacterial origin. 9% of patients treated with anti-COVID-19 MAb still required hospitalisation due to COVID-19;the other patients recovered completely.Conclusion and relevanceTogether with the home care protocol and vaccines, MAb constitute a valid weapon in the early phase of COVID-19 disease. It is an important opportunity because it allows the virus to be faced in an active way, without waiting for the worsening of the patient’s clinical condition, and with a synergistic approach of hospital and territory that join forces against this great infectious disease challenge.References and/or acknowledgementsConflict of interestNo conflict of interest
{"title":"5PSQ-005 Analysis of the use of monoclonal antibodies for the treatment of COVID-19 in clinical practice: a weapon in the fight against the pandemic, alongside vaccination","authors":"G. Pellegrino, E. Grande, E. Bersia, E. Bastonero, M. Rebora, C. Fruttero","doi":"10.1136/ejhpharm-2022-eahp.418","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.418","url":null,"abstract":"Background and importanceVaccines are emerging as a fundamental tool in the prevention of COVID-19 disease but are not decisive in treating it, once contracted. Anti COVID-19 monoclonal antibodies (MAb) define a valuable and parallel resource for the treatment of coronavirus infection so it is useful to monitor the usage data, adverse reactions (ADRs) and percentage of hospitalisations after treatment.Aim and objectivesPurpose of the work was to provide data on safety and efficacy of anti-COVID MAb in consideration of their use in current clinical practice.Material and methodsUsing a home-made database, the pharmacy extrapolated and reprocessed the data relating to the reports of patient recruitment by local and hospital clinicians, the number of patients who were treated, the specific therapies administered (bamlanivimab, bamlanivimab/etesevimab or casirivimab/imdevimab) and ADRs reported by doctors.In parallel, the infectious diseases department monitored the percentage of patients who still needed hospitalisation after the infusion of MAb.ResultsMost of the recruitment reports were received from general doctors (82% vs 18% from hospitals) and, from March 2021 to September 2021, 104 patients were treated: 48 patients (46.2%) with bamlanivimab/etesevimab, 55 (52.9%) with casirivimab/imdevimab and 1 (0.9%) with bamlanivimab. 67% of patients were not vaccinated while 33% received at least one dose of vaccine (58%: first dose;42%: two doses). The main comorbidity found was the cardiological/cerebral/vascular type.Following outpatient dosing, 2 ADRs have been reported: an emetic episode after bamlanivimab infusion and a subacute antero-septal myocardial infarction with acute pulmonary oedema occurring within hours after administration of casirivimab/imdevimab and in the presence of a septic event of bacterial origin. 9% of patients treated with anti-COVID-19 MAb still required hospitalisation due to COVID-19;the other patients recovered completely.Conclusion and relevanceTogether with the home care protocol and vaccines, MAb constitute a valid weapon in the early phase of COVID-19 disease. It is an important opportunity because it allows the virus to be faced in an active way, without waiting for the worsening of the patient’s clinical condition, and with a synergistic approach of hospital and territory that join forces against this great infectious disease challenge.References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"90 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130248975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.419
Z. Rodríguez Fernández, B. Távara Silva, B. Matilla Fernández, X. Casás Fernández, A. Vélez Blanco, JC Sáez Hortelano, C. De Castro Avedillo, R. Varela Fernández, A. Martín Sanz, C. Guindel Jiménez, C. Arenós Monzó
{"title":"5PSQ-024 Effectiveness and safety of durvalumab in the treatment of unresectable locally advanced non-small-cell lung cancer (LA-NSCLC)","authors":"Z. Rodríguez Fernández, B. Távara Silva, B. Matilla Fernández, X. Casás Fernández, A. Vélez Blanco, JC Sáez Hortelano, C. De Castro Avedillo, R. Varela Fernández, A. Martín Sanz, C. Guindel Jiménez, C. Arenós Monzó","doi":"10.1136/ejhpharm-2022-eahp.419","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.419","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128951234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.410
A. Aguado Paredes, M. Valera Rubio, L. Moñino-Dominguez
{"title":"4CPS-245 Inappropriate antibiotic dosage adjustments in patients with renal impairment: a cross-sectional analysis","authors":"A. Aguado Paredes, M. Valera Rubio, L. Moñino-Dominguez","doi":"10.1136/ejhpharm-2022-eahp.410","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.410","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"406 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115236926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.402
T. Grillitsch, IM Lagoja
{"title":"4CPS-181 Clinical-pharmaceutical medication counselling for pneumological patients in outpatient and inpatient areas","authors":"T. Grillitsch, IM Lagoja","doi":"10.1136/ejhpharm-2022-eahp.402","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.402","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116258638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：